ClinicalTrials.gg
CompletedNCT01688635Updated Oct 7, 2014Results posted

A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants

A Phase 1 interventional study of LY2963016 and US Approved Lantus in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to compare the pharmacokinetics and pharmacodynamics of LY2963016 and US-approved Lantus®. The study involves four single injections; two doses of LY2963016 and two doses of US-approved Lantus®. The study will have 4 periods. In each period, a single injection will be administered before undergoing a euglycemic clamp that lasts for 24 hours. There will be at least a 7 day washout between each period. Side effects will be documented. Study participation is expected to last up to 14 weeks.

02

Conditions studied

  • Healthy

Keywords

  • Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or females
  • Have between 18.5 and 29.9 kilograms per meter square (kg/m\^2)
  • Are nonsmokers and have not smoked for at least 2 months prior to entering the study
  • Have normal blood pressure and pulse rates at screening
  • Have (ECGs) at screening considered as within normal limits
  • Have clinical laboratory test results within normal reference ranges

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in or discontinued within the last 30 days from a clinical study involving an drug or device or are concurrently enrolled in any other type of medical research
  • Have known allergies to insulin, its , or related drugs or have history of relevant allergic reactions of any origin
  • Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders
  • Show evidence of significant active neuropsychiatric disease, including taking prescription medication for such diseases
  • Show evidence of current use of known drugs of abuse or a history of use within the past year
  • Have a history of first-degree relatives known to have diabetes mellitus
  • Show evidence of (HIV) infection and/or positive human HIV antibodies at screening
  • Have positive surface antigen at screening
  • Intend to use over-the-counter or prescription medication within 7 or 14 days, respectively, prior to dosing (apart from vitamin/mineral supplements, occasional paracetamol, thyroid replacement medication, or methods)
  • Have donated or had a blood loss of 450 milliliters (mL) within 3 months prior to study enrollment
  • Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females) or are unwilling to stop alcohol consumption from 24 hours prior to each dosing until discharged from the clinical research unit (CRU)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    LY2963016

    Single 0.5 units per kilogram (U/kg) dose of LY2963016 administered subcutaneously, twice during the study

    Drug: LY2963016

  • Experimental
    US-approved Lantus

    Single 0.5 U/kg dose of US-approved Lantus administered subcutaneously, twice during the study

    Drug: US Approved Lantus

Interventions

  • Administered subcutaneously

  • DrugUS Approved Lantus

    Administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY2963016 and US-Approved Lantus

    The AUC from time 0 to 24 hours (AUC0-24) of LY2963016 and US-Approved Lantus was measured.

    Time frame: 30 minutes predose up to 24 hours postdose in all treatment periods

  2. Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY2963016 and US-Approved Lantus

    Time frame: 30 minutes predose up to 24 hours postdose in all treatment periods

Secondary outcomes

  1. Maximum Glucose Infusion Rate (Rmax)

    Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain target blood glucose level and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or US-approved Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.

    Time frame: 30 minutes predose up to 24 hours postdose in all treatment periods

  2. Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure

    Gtot was the total glucose infusion over the clamp duration and was used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations were held constant after the administration of LY2963016 or US-approved Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.

    Time frame: 30 minutes predose up to 24 hours postdose in all treatment periods

07

Results

Posted Oct 7, 2014

Participant flow

Period 1
Participant flow — Period 1
MilestoneLY/Lantus/LY/LantusLantus/LY/Lantus/LY
Started4546
Received at least 1 dose of study drug4546
Completed4546
Not completed00
Washout 1
Participant flow — Washout 1
MilestoneLY/Lantus/LY/LantusLantus/LY/Lantus/LY
Started4546
Completed4444
Not completed12
Withdrew: Withdrawal by subject10
Withdrew: Adverse event01
Withdrew: Physician decision01
Period 2
Participant flow — Period 2
MilestoneLY/Lantus/LY/LantusLantus/LY/Lantus/LY
Started4444
Completed4444
Not completed00
Washout 2
Participant flow — Washout 2
MilestoneLY/Lantus/LY/LantusLantus/LY/Lantus/LY
Started4444
Completed4142
Not completed32
Withdrew: Physician decision10
Withdrew: Withdrawal by subject10
Withdrew: Sponsor decision12
Period 3
Participant flow — Period 3
MilestoneLY/Lantus/LY/LantusLantus/LY/Lantus/LY
Started4142
Completed4142
Not completed00
Washout 3
Participant flow — Washout 3
MilestoneLY/Lantus/LY/LantusLantus/LY/Lantus/LY
Started4142
Completed4042
Not completed10
Withdrew: Withdrawal by subject10
Period 4
Participant flow — Period 4
MilestoneLY/Lantus/LY/LantusLantus/LY/Lantus/LY
Started4042
Completed4042
Not completed00

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY2963016 and US-Approved Lantus

The AUC from time 0 to 24 hours (AUC0-24) of LY2963016 and US-Approved Lantus was measured.

Time frame:
30 minutes predose up to 24 hours postdose in all treatment periods
Reported as:
Geometric mean · picomoles*hour/liter (pmol*h/L)
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY2963016 and US-Approved Lantus
picomoles*hour/liter (pmol*h/L)LY2963016US-approved Lantus
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY2963016 and US-Approved Lantus1720 ± 421900 ± 35
PrimaryPharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY2963016 and US-Approved Lantus
Time frame:
30 minutes predose up to 24 hours postdose in all treatment periods
Reported as:
Geometric mean · picomoles/liter (pmol/L)
Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY2963016 and US-Approved Lantus
picomoles/liter (pmol/L)LY2963016US-approved Lantus
Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY2963016 and US-Approved Lantus103 ± 41111 ± 34
SecondaryMaximum Glucose Infusion Rate (Rmax)

Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain target blood glucose level and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or US-approved Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.

Time frame:
30 minutes predose up to 24 hours postdose in all treatment periods
Reported as:
Geometric mean · milligrams/kilograms/minute (mg/kg/min)
Maximum Glucose Infusion Rate (Rmax)
milligrams/kilograms/minute (mg/kg/min)LY2963016US-approved Lantus
Maximum Glucose Infusion Rate (Rmax)2.12 ± 542.27 ± 58
SecondaryTotal Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure

Gtot was the total glucose infusion over the clamp duration and was used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations were held constant after the administration of LY2963016 or US-approved Lantus by adjusting the exogenous glucose infusion rate. Data presented were adjusted by the body weight.

Time frame:
30 minutes predose up to 24 hours postdose in all treatment periods
Reported as:
Geometric mean · milligrams/kilogram (mg/kg)
Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure
milligrams/kilogram (mg/kg)LY2963016US-approved Lantus
Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure1670 ± 601820 ± 74

Adverse events

Collected over Randomization to study completion. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY2963016—0/89 (0%)42/89 (47.2%)
US-approved Lantus—0/90 (0%)42/90 (46.7%)
Most frequent other events
Most frequent other events
EventLY2963016US-approved Lantus
Catheter site haematomaGeneral disorders10/899/90
Catheter site swellingGeneral disorders9/897/90
HeadacheNervous system disorders3/898/90
Catheter site painGeneral disorders5/896/90
Infusion site swellingGeneral disorders2/895/90
Infusion site painGeneral disorders4/894/90
PyrexiaGeneral disorders4/891/90
Oropharyngeal painRespiratory, thoracic and mediastinal disorders4/893/90
Procedural site reactionInjury, poisoning and procedural complications2/894/90

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)LY2963016 and US-approved Lantus
Mean32.7 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)LY2963016 and US-approved Lantus
Female6
Male85
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)LY2963016 and US-approved Lantus
Asian90
White1
Region of Enrollment
Region of Enrollment(participants)LY2963016 and US-approved Lantus
Singapore91
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Singapore, 117597, Singapore
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2012
First posted
Sep 20, 2012
Start
Sep 2012
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results first posted
Oct 7, 2014
Last update
Oct 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01688635
Responsible party
Sponsor
First posted
Sep 20, 2012
Start date
Sep 2012
Primary completion
Feb 2013
Completion
Feb 2013
Results posted
Oct 7, 2014
Last update
Oct 7, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion